Peptides

A synthetic peptide for use as a blocking control in assays to test for specificity of LRRC33 antibody, catalog no. 70R-7545

A synthetic peptide for use as a blocking control in assays to test for specificity of HNRPH3 antibody, catalog no. 70R-1326

A synthetic peptide for use as a blocking control in assays to test for specificity of RNF20 antibody, catalog no. 70R-2098

Methoxytrityl-S-dPEG®4 Acid is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. Methoxytrityl-S-dPEG®4 Acid is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

Amino-dPEG® Acid is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. Amino-dPEG® Acid is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

Kisspeptin-10 (Rat) / Metastin (Rat, 43-52) is a Research Tool that belongs to the group of Activators and Ligands. It is an agonist for G protein coupled receptor 54 (GPR54). Kisspeptin-10 (Rat) / Metastin (Rat, 43-52) has been shown to inhibit ion channels and act as a potent inhibitor of phosphoinositide 3-kinase. This compound has high purity and can be used in pharmacological research.

Urinary Trypsin Inhibitor-Ulinastatin Human is a protein that is found in human urine. This protein was originally identified as an autoantigen in patients with the tripartite syndrome, which consists of nephrotic syndrome, skin lesions and lymphocytic infiltration. The protein is also found to be involved in the development of type 1 diabetes and other autoimmune disorders. Urinary Trypsin Inhibitor-Ulinastatin Human may be a ribonucleoprotein or a proteinase inhibitor. It has been shown to inhibit trypsin activity on Escherichia coli cells.

A synthetic peptide for use as a blocking control in assays to test for specificity of ERAL1 antibody, catalog no. 70R-4906

Sourced from the marine snail, conus striatus, this synthetic cone snail toxin is a nicotinic acetylcholine receptor blocker. This product has disulfide bonds between Cys2-Cys7 and Cys3-Cys7.

A synthetic peptide for use as a blocking control in assays to test for specificity of RNASE11 antibody, catalog no. 70R-5391

A synthetic peptide for use as a blocking control in assays to test for specificity of ARMCX1 antibody, catalog no. 70R-6313

A synthetic peptide for use as a blocking control in assays to test for specificity of PSMD12 antibody, catalog no. 70R-4476

A synthetic peptide for use as a blocking control in assays to test for specificity of FETUB antibody, catalog no. 70R-5424

Parathyroid hormone (PTH) is a peptide hormone that regulates the calcium and phosphate concentrations in the blood. It is produced by the parathyroid gland, located near the thyroid gland in the neck. PTH has three forms: amino-terminal proparathyroid hormone (PTH 1-34), amino-terminal parathyroid hormone fragment 34-84 (PTH 1-34 amide), and carboxy-terminal parathyroid hormone fragment 84-120 (PTH 1-84). The receptor for PTH is called the parathyroid hormone receptor (PTR). The binding of PTH to its receptor leads to activation of adenylate cyclase, which increases levels of intracellular cAMP.

A synthetic peptide for use as a blocking control in assays to test for specificity of Pde4b antibody, catalog no. 70R-9379

A synthetic peptide for use as a blocking control in assays to test for specificity of CLN8 antibody, catalog no. 70R-7114

A synthetic peptide for use as a blocking control in assays to test for specificity of BCL11A antibody, catalog no. 70R-8336

A synthetic peptide for use as a blocking control in assays to test for specificity of ZFYVE27 antibody, catalog no. 70R-1729

A synthetic peptide for use as a blocking control in assays to test for specificity of ERLIN1 antibody, catalog no. 70R-7393

A synthetic peptide for use as a blocking control in assays to test for specificity of GSG1 antibody, catalog no. 70R-7537

A synthetic peptide for use as a blocking control in assays to test for specificity of MTUS1 antibody, catalog no. 70R-7029

Peptide YY (PYY) is a peptide hormone that inhibits gastric emptying and increases intestinal transit time. This peptide can be given as an intubation, perfusion, or intravenous infusion to increase the absorption of nutrients. It also has the potential to reduce body weight in obese people. PYY is a potent activator of protein synthesis and it has been shown to stimulate lipolysis in adipocytes. PYY is found in the ileum and colon, where it may have its effects on appetite suppression and regulation of gastrointestinal motility.

Cysteine peptide (Ac RFAAKAA COOH) is used in combination with Lysinepeptide (Ac RFAACAA COOH) in the Direct Peptide Reactivity Assay (DPRA) test.
Direct Peptide Reactivity Assay is used in cosmetic applications for the characterization of the skin sensitizing potential of a substance, framed by OECD Guideline no 442.
The molecular initiating event (MIE) in skin sensitization is a binding between epidermal proteins and the sensitizing chemical substance. MIE is part of the adverse outcome pathway (AOP) of skin sensitization.
It is thanks to the properties of Lysine peptide and Cysteine peptide that the chemical binding will be able to take place, so these synthetic heptapeptides will mimic the reaction of a skin exposed to a substance.
Binding between nucleophilic proteins and electrophile substance will be measured by High Performance Liquid Chromatography (HPLC). Therefore, the decrease in Lysine peptide and Cysteine peptide levels will be a sign of sensitizing event. Depending on the rate of depletion, the sensitizing character of a molecule will be determined (see table at the bottom of the page).
In chemico DPRA test also has wider applications such as hazard classification in cosmetics, but also for pharmaceuticals and biocides. It is a good alternative to animal experimentation.

SB-peptide offers the scrambled version of OVA 257-264. FILKSINE can be used as a negative control of OVA 257-264 studies.
SB-peptide offers also OVA 257-264 (see section OVA 257-264).
Ovalbumin protein:
OVA 257-264 (H-2Kb) is an epitope of interest of the egg white albumen, ovalbumin. Ovalbumin is a glycoprotein that is sufficiently large and complex to be mildly immunogenic. Indeed, it has been demonstrated that Ovalbumin contains B-cell epitopes which are recognized by specific IgE antibodies and CD4 T cell epitopes restricted by the MHC I-Ad molecule in mice and by HLA-D molecule in human.
Applications of OVA 257-264:
OVA 257-264 is used to stimulate T cells in PBMCs and to quantify peptide epitope specificity and IFN-γ releasing effector cells by ELISPOT assay. OVA 257-264 is also used to test new adjuvant in immunotherapeutic vaccine development. OVA 257-264 can form a stable hydrogel and stimulate a immune response. This reaction seems to be linked with OVA 257-264 property to self-assemble into a hydrogel.
Sequence:C45H74N10013

TentaGel based resin for protected peptide amides; particle size: 90 µmcapacity: 0.18 - 0.25 mmol/g

Nav1.3 activator

Blocker of Nav1.4 channels

Custom research peptide; min purity 95%.

Fibronectin is an extracellular matrix protein that plays a critical role in cell adhesion, migration, and differentiation. Fibronectin subunits are composed of repeating units of three types of modules: type I, type II, and type III. The active fragment of fibronectin refers to a small peptide sequence within the type III modules of fibronectin that has been shown to have potent biological activity.
The fibronectin active fragment, also known as the cell-binding domain or RGD domain, is a short peptide sequence consisting of the amino acid sequence Arg-Gly-Asp (RGD). This peptide sequence interacts with cell surface receptors known as integrins, which are important for mediating cell adhesion, migration, and signaling.
The fibronectin active fragment has been extensively studied as a research tool to investigate the mechanisms of cell adhesion and migration. It has also been used in tissue engineering applications to promote cell attachment and proliferation on synthetic biomaterials.

A synthetic peptide for use as a blocking control in assays to test for specificity of ALKBH8 antibody, catalog no. 70R-1459

AMC is a peptide that acts as an activator of the nicotinic acetylcholine receptor. AMC is a high-purity, ion channel ligand with a CAS No. 26093-31-2. It is used in life science research to study cell biology and pharmacology. AMC has been shown to be an inhibitor of the enzyme acetylcholinesterase (AChE) in rat brain slices and it has been reported that it can inhibit the proliferation of human leukemia cells.END>

A synthetic peptide for use as a blocking control in assays to test for specificity of SLC29A2 antibody, catalog no. 70R-7165

A synthetic peptide for use as a blocking control in assays to test for specificity of Arf4 antibody, catalog no. 70R-9371

A synthetic peptide for use as a blocking control in assays to test for specificity of LRRC50 antibody, catalog no. 70R-3357

A synthetic peptide for use as a blocking control in assays to test for specificity of PLEKHA9 antibody, catalog no. 70R-3896

A synthetic peptide for use as a blocking control in assays to test for specificity of GDE1 antibody, catalog no. 70R-7477

A synthetic peptide for use as a blocking control in assays to test for specificity of LSM2 antibody, catalog no. 70R-1438

A synthetic peptide for use as a blocking control in assays to test for specificity of CDC2 antibody, catalog no. 70R-5614

A synthetic peptide for use as a blocking control in assays to test for specificity of FBN1 antibody, catalog no. 70R-8232

Catalogue peptide; min. 95% purity

H-His-Arg-OH is a synthetic peptide that has been shown to have cytotoxic effects on mammalian cells. The H-His-Arg-OH peptide can be used for the treatment of heart disease and autoimmune diseases, such as rheumatoid arthritis. This peptide has been found to be resistant to congestive heart failure, which is caused by a number of factors, including hypertension and valvular stenosis. It has also been shown to have an immunoglobulin G1 (IgG1) genotype.

Please enquire for more information about N-(2-Amino-ethyl)-2-(benzyl-phenyl-amino)-acetamide including the price, delivery time and more detailed product information at the technical inquiry form on this page

Catalogue peptide; min. 95% purity

Cymit Quimica provides this product solely for uses within the scope of any statute or law providing for an immunity, exemption, or exception to patent infringement (“Exempted Uses”), including but not limited to 35 U.S.C. § 271(e)(1) in the United States, the Bolar type exemption in Europe, and any corresponding exception to patent infringement in any other country. It is the sole responsibility of the purchaser or user of this product, and the purchaser or user of this product agrees to engage only in such Exempted Uses, and to comply with all applicable intellectual property laws and/or regulations. The purchaser of this product agrees to indemnify Cymit Quimica against all claims in connection with the performance of the respective commercial agreement (e.g. supply agreement) and possible infringements of intellectual property rights.

Catalogue peptide; min. 95% purity

CJC-1295 is a synthetic peptide, which is an analogue of growth hormone-releasing hormone (GHRH). It is synthesized through recombinant DNA technology, which allows for precise control over its sequence and length. This particular peptide is designed to bind to GHRH receptors in the pituitary gland. By activating these receptors, CJC-1295 stimulates the release of growth hormone (GH) into the bloodstream.The primary function of CJC-1295 is to influence the endocrine system, particularly enhancing the release of endogenous growth hormone. It achieves this by increasing the amplitude and frequency of GH pulses without affecting the natural negative feedback mechanisms that regulate GH production. This mode of action distinguishes CJC-1295 from other growth hormone therapies, as it promotes a more physiological pattern of hormone secretion.CJC-1295 is used in various scientific contexts, primarily in research focusing on growth hormone deficiencies, muscle wasting conditions, and certain metabolic disorders. Its ability to increase GH release also makes it a subject of interest in studies related to aging, tissue repair, and regeneration. The longer half-life of CJC-1295 compared to natural GHRH peptides further enhances its applications in research, allowing for more sustained and controlled experimentation.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Please enquire for more information about ([ring-D5]Phe8)-Angiotensin II acetate salt including the price, delivery time and more detailed product information at the technical inquiry form on this page

Please enquire for more information about Suc-Leu-Leu-Val-Tyr-pNA including the price, delivery time and more detailed product information at the technical inquiry form on this page

Seglitide is a cyclic peptide that is a model system for the receptor activity of somatostatin. Somatostatin inhibits cells by binding to its receptors, which are found on the surface of endocrine cells and in the hypothalamus. Seglitide has been shown to inhibit cell growth in tissue culture and is a potent inhibitor of epidermal growth factor (EGF) production. Seglitide also activates locomotor activity in mice, suggesting that it may have some clinical relevance. Structural analysis has revealed that seglitide's amino acid sequence is similar to somatostatin's, making them closely related compounds. It also binds to DNA-dependent RNA polymerase, preventing transcription and replication.

Catalogue peptide; min. 95% purity

Myelin oligodendrocyte glycoprotein (MOG) is a myelin protein found in the central nervous system. MOG is a ligand for CD200, which is an inhibitory receptor expressed by astrocytes. It has been shown that MOG can induce the proliferation and differentiation of primary cultures of rat astrocytes in vitro. MOG induces the production of reactive oxygen species in mitochondria and increases the expression of acid-binding protein, which are both important factors in the demyelination process. MOG has also been implicated as a potential factor in the development of multiple sclerosis. Further research into this protein may lead to new treatments or cures for disorders such as encephalomyelitis, nervous system diseases, or even cancer.

Catalogue peptide; min. 95% purity

Please enquire for more information about H-D-Asp(OtBu)-allyl ester·HCl including the price, delivery time and more detailed product information at the technical inquiry form on this page

Please enquire for more information about H-Ile-Arg-Pro-OH including the price, delivery time and more detailed product information at the technical inquiry form on this page

Adriamycin is an anticancer drug that is a structural analogue of aspartic acid. It can be synthesized in a solid-phase synthesis using a polymeric resin with an acidic functional group, such as H-Asp-Ala-OH. Adriamycin inhibits the production of inflammatory cytokines and prostaglandins, which are involved in the development of inflammatory diseases. Adriamycin has been shown to have anti-inflammatory effects on human serum and to inhibit the production of proteins important for tumor cell proliferation. Adriamycin also has anti-inflammatory properties due to its ability to bind with hydrogen bonds to acidic residues on proteins.
END>

Catalogue peptide; min. 95% purity